================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------------
FORM 8-K
--------------------
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 12, 2005
--------------------
BIOENVISION, INC.
(Exact name of registrant as specified in its charter)
--------------------
Delaware
(State or other jurisdiction of incorporation)
000-24875 13-4025857
(Commission File No.) (IRS Employer Identification No.)
345 Park Avenue, 41st Floor
New York, New York 10154
(Address of principal executive offices and zip code)
--------------------
Registrant's telephone number, including area code: (212) 750-6700
N/A
---
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
================================================================================
--------------------------------------------------------------------------------
Item 2.02. Results of Operations and Financial Condition.
On October 12, 2005, the Company issued a press release reporting 2005
year-end financial results. The press release is attached as Exhibit 99.1 to
this report. Due to a clerical error, the issued press release stated that the
net loss available to shareholders was $0.31 per share for the three months
ended June 30, 2005 when it should have stated $0.35. This error has been
corrected in the press release attached to this report.
The information set forth in the above Item 2.02 and the attached
Exhibit 99.1 is furnished to, but shall not be deemed "filed" with the
Commission for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), or otherwise incorporated by reference
into any filing pursuant to the Securities Act of 1933, as amended, or the
Exchange Act, except as otherwise expressly stated in such a filing.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press Release dated October 12, 2005.
-2-
--------------------------------------------------------------------------------
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
BIOENVISION, INC.
Dated: October 14, 2005 By: /s/ David P. Luci
------------------------------
David P. Luci
Chief Financial Officer,
General Counsel and Corporate
Secretary
-3-
EXHIBIT INDEX
99.1 Press Release dated October 12, 2005.
-4-